Patents Assigned to Trellis Bioscience, LLC
-
Patent number: 12152068Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: January 5, 2022Date of Patent: November 26, 2024Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Patent number: 11773143Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: GrantFiled: October 12, 2018Date of Patent: October 3, 2023Assignees: Trellis Bioscience, LLC, The Regents of the University of CaliforniaInventors: Rebecca Dubois, Stas Fedechkin, Lawrence M. Kauvar
-
Publication number: 20210268096Abstract: Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.Type: ApplicationFiled: February 5, 2021Publication date: September 2, 2021Applicant: Trellis Bioscience, LLCInventors: Milton J. Friedman, Lawrence M. Kauvar
-
Patent number: 11046764Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.Type: GrantFiled: January 3, 2018Date of Patent: June 29, 2021Assignee: Trellis Bioscience, LLCInventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
-
Publication number: 20210054075Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.Type: ApplicationFiled: November 6, 2020Publication date: February 25, 2021Applicant: Trellis Bioscience, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
-
Patent number: 10858431Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.Type: GrantFiled: June 9, 2017Date of Patent: December 8, 2020Assignee: Trellis Bioscience, LLCInventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
-
Patent number: 10570193Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: November 5, 2018Date of Patent: February 25, 2020Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Publication number: 20190135876Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: ApplicationFiled: October 12, 2018Publication date: May 9, 2019Applicants: Trellis Bioscience, LLC, The Regents of the University of CaliforniaInventors: Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
-
Patent number: 10233234Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: May 2, 2016Date of Patent: March 19, 2019Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Publication number: 20190055304Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: November 5, 2018Publication date: February 21, 2019Applicant: Trellis Bioscience, LLCInventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
-
Patent number: 10030069Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: GrantFiled: March 20, 2017Date of Patent: July 24, 2018Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
-
Publication number: 20180186880Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.Type: ApplicationFiled: January 3, 2018Publication date: July 5, 2018Applicant: Trellis Bioscience, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
-
Publication number: 20180002420Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.Type: ApplicationFiled: June 9, 2017Publication date: January 4, 2018Applicant: Trellis Bioscience, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
-
Publication number: 20170204165Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: ApplicationFiled: March 20, 2017Publication date: July 20, 2017Applicant: Trellis Bioscience, LLCInventors: Lawrence M. KAUVAR, Stote ELLSWORTH, William USINGER, Krista Maureen MCCUTCHEON, Ying-Ping JIANG, Fen ZHANG, Bo CHEN, Gizette SPERINDE, Minha PARK, Orit FOORD
-
Patent number: 9688744Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: GrantFiled: April 27, 2015Date of Patent: June 27, 2017Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
-
Publication number: 20160237145Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: May 2, 2016Publication date: August 18, 2016Applicant: Trellis Bioscience, LLCInventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON
-
Patent number: 9017668Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: GrantFiled: June 16, 2011Date of Patent: April 28, 2015Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
-
Patent number: 8828388Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.Type: GrantFiled: January 17, 2013Date of Patent: September 9, 2014Assignee: Trellis Bioscience, LLCInventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
-
Publication number: 20130122000Abstract: Antibodies which specifically bind heregulin-coupled HERS, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.Type: ApplicationFiled: January 17, 2013Publication date: May 16, 2013Applicant: Trellis Bioscience, LLCInventor: Trellis Bioscience, LLC
-
Patent number: 8362215Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.Type: GrantFiled: April 29, 2010Date of Patent: January 29, 2013Assignee: Trellis Bioscience, LLCInventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
